Drug Trial Radar · NCT00794885
China Stroke Primary Prevention Trial
Last checked: Nov 19, 2026Latest source record: Aug 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20,702
Actual
Start
May 2008
Primary completion
Aug 2013
Study completion Jun 2014
Sponsor
- Lead sponsor
- Shenzhen Ausa Pharmed Co.,LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Anhui Medical University
- First posted
- Nov 20, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.
Conditions
- Primary Hypertension
Interventions
Enalapril/folic acidDrug
Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
Enalapril maleateDrug
Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- First attack of symptomatic stroke ( ischemic or hemorrhagic)Time frame: during the trial period
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Anqing Branch, Anhui Institute of Biomedical Research
Anqing, Anhui, China
Lianyungang Center for Advanced Research in Cardiovascular Diseases
Lianyungang, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.